Cardiology
FDA Approves Cardamyst Spray for PSVT
The FDA approved Cardamyst nasal spray for episodes of paroxysmal supraventricular tachycardia in adults.
DECEMBER 18, 2025
Pharmacist-Led Program Improves Hypertrophic Cardiomyopathy Outcomes
The first-in-class cardiac myosin inhibitor Camzyos can be an effective treatment for hypertrophic cardiomyopathy, ...
SEPTEMBER 9, 2025
A Difficult Act—Balancing Heart Health and Treating RA
Guidelines from the American College of Rheumatology recommend that clinicians treating rheumatoid arthritis with ...
FEBRUARY 9, 2025
Pharmacists Key Players on AFib Treatment Teams
Pharmacists are crucial, but often overlooked and underrepresented, members of the care team for patients with ...
NOVEMBER 12, 2024
Heart Rhythm Monitoring Tools Helpful When Used Judiciously
Pharmacists, nurse practitioners and physician assistants are all essential to helping patients understand ECG data ...
OCTOBER 2, 2024
Pharmacist-Managed Remote Heart Failure Program Shows Promise
A pharmacist-managed remote heart failure program that relies on data from multisensor implantable cardiac devices ...
AUGUST 29, 2024
Report: GLP-1 Adherence Rates Lower Than Expected
Although more than 90% of patients adhered to GLP-1 agonists through the end of clinical trials, new data suggest ...
MAY 23, 2024
Community Partnership Boosts BP Control
A University of Michigan initiative that integrated specially trained community pharmacists into hypertension ...
MAY 10, 2024
Cardio-Oncology Yields Opportunities For Patient-Centered Care
Oncology pharmacists should collaborate with cardiologists and patients to navigate the cardiovascular risks of ...
MARCH 19, 2024
Appropriate Statin Use Soars When Pharmacists on Board
The odds of prescribing the appropriate dose of statins increased sixfold when automated referrals were made to ...
MARCH 14, 2024
AHA Recommends Oral Penicillin, Not Injectable, for Some Rheumatic Heart Disease Patients
A growing body of evidence indicates that some people may have experienced a cardiac reaction to the injectable ...
JANUARY 20, 2022
Novel Agent for HF Shows Mixed Results in Large Trial
The novel selective cardiac myosin activator omecamtiv mecarbil reduced a composite of a HF event or death from ...
JULY 22, 2021
